Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Donaldm who wrote (527)	1/29/1998 2:13:00 PM
From: FNS	Read Replies (1) of 965

Thanks Donaldm: A lotta stuff published today. Also, Hambrecht & Quist raised its rating to BUY from HOLD due to CNTO's competitve position of ReoPro and in advance of rollout of Avakine. (Didn't indicate the links cause I beieve restricted to Fidelity Web Express participants. <<Holveck cited the FDA filing for Avakine in Crohn's disease, expanded labeling for ReoPro and the continued progress shown in clinical trials with ReoPro for expanded indications in acute coronary syndromes and for Avakine in rheumatoid arthritis.....>> So, while CORR got shot down on expanded coronary syndromes it looks like CNTO is continuing trials; thus, we can expect news later in year! Lots of news out...stock acting well on 4.6 M shares...however, I would expect some profit taking in here and to reconsolidate (don't know where but 37-38 is reasonable)...in weeks to come, expectations for Avakine should move stock higher. Basically, what H & Q are saying, IMO. FNS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next